Sandostatin LAR 30 mg prašak i otapalo za suspenziju za injekciju
| Name | Sandostatin LAR 30 mg prašak i otapalo za suspenziju za injekciju |
|---|---|
| Marketing Authorisation Number | HR-H-983646054 |
| Active Substance | oktreotidacetat |
| Composition | jedna bočica sadrži 30 mg oktreotida (u obliku oktreotidacetata) |
| Pharmaceutical Form | prašak i otapalo za suspenziju za injekciju |
| Manufacturer | Novartis Pharma GmbH, Nürnberg, Njemačka
Novartis Farmacéutica S.A., Barcelona, Španjolska |
| Marketing Authorisation Holder | Novartis Hrvatska d.o.o., Radnička cesta 37b, Zagreb, Hrvatska |
| Marketing Authorisation Date | 13.03.2019 |
| MA Period of Validity | unlimited |
| Classification Number | UP/I-530-09/19-02/14 |
| Registration Number | 381-12-01/70-19-02 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ograničeni recept |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | H01CB02 |
| Marketing status | stavljeno u promet |
| Shortage status | nema nestašice |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
